An observational study in Corona Virus Infection, Flu Vaccine and Immunity, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 9 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Stanford University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 401 studies in Coronavirus Infections with a site in United States — 29 open to participants now, 40 under way, 7 of them phase 3. Coronavirus Infections · United States.
Among the 401 studies in Coronavirus Infections with a site in United States, this one is the 73rd largest by planned enrollment of the 112 observational ones that give a count, is one of 252 that started in 2020, is one of 112 observational ones, reaches primary completion later than 33 of the 38 other live ones, and was the 248th registered.
1,112 studies on the registry are indexed under Coronavirus Infections; 51 are open to participants now.
Browse Coronavirus Infections studies →29 of the 401 studies in Coronavirus Infections with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Kara Chew · Sites in United States
Ages 40–64 · Healthy volunteers
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Coronavirus Infections studies recruiting now, 23 (59%) set no upper age limit and 9 (23%) stop at 75 or younger; 12 take children under 18; 19 take healthy volunteers.
This study: 9 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
401 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 122 · Phase 3 70 · Phase 4 21
First in 2003; this study’s year is marked. 252 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 230 is below the median of 308 across 387 observational studies indexed under Coronavirus Infections.
Median enrollment 94 across the 283 interventional studies, 428 across the 112 observational. Of the 313 that completed or were terminated, 171 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
146 of 401 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Stanford University has 4 studies filed under Coronavirus Infections — fewer than ten, so there is no comparison to draw.
20 of the studies in Coronavirus Infections with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
Add all 20 to your calendar (.ics) → With an account.
Among the 401 studies in Coronavirus Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.
Adults (18-64 years) and children (9-17 years) diagnosed and not diagnosed (controls) with COVID-19 and who may have other medical conditions including long term COVID-19 symptoms, chronic fatigue, type 2 diabetes, and obesity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Flu shot
Biological: Flu shot
All participants will receive a single shot of the flu vaccine
Testing immunity to the flu vaccine over time
Time frame: 1 week
Testing immunity to the flu vaccine over time
Time frame: 1 month
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2020 (actual). Primary completion is estimated for Apr 2028, 90 months after the start.
Of 228 non-industry observational studies under Coronavirus Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 90 months is above that.
Counting every sponsor, half of 245 studies reached it within 14 months; a quarter within 5 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.